Form 4: Acrivon Therapeutics Executives Report Share Transactions
SEC Form 4 Filing
Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, and EVP of Business Operations, Kristina Masson, reported transactions involving company stock, including shares withheld for tax obligations and indirect holdings.
Summary
- Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, had 19,910 shares of common stock withheld by the company on November 21, 2024, to cover tax obligations related to vesting restricted stock units.
- The price per share for the tax withholding was $6.44.
- Following the transaction, Peter Blume-Jensen directly owns 2,342,837 shares of common stock.
- Peter Blume-Jensen also indirectly owns 316,756 shares of common stock through his spouse, Kristina Masson.
- Kristina Masson, EVP of Business Operations, indirectly owns 2,342,837 shares of common stock through her spouse, Peter Blume-Jensen.
- Kristina Masson directly owns 316,756 shares of common stock.
- Both Peter Blume-Jensen and Kristina Masson disclaim beneficial ownership of shares held by their spouse, except to the extent of their pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not contain any information that would indicate positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, which is required when company insiders trade shares. It provides transparency into the transactions of key personnel.
Comparison to Industry Standards
- Form 4 filings are a common practice for publicly traded companies, and the transactions reported here are typical for executives receiving stock-based compensation.
- The tax withholding is a standard procedure when restricted stock units vest.
Stakeholder Impact
- The transactions reported in this filing provide transparency to shareholders regarding the stock holdings of key executives.
Key Dates
| Date | Description |
|---|---|
| 11/21/2024 | Date of the stock transaction where shares were withheld for tax obligations. |
| 11/25/2024 | Date the Form 4 was signed by the attorney-in-fact for both Peter Blume-Jensen and Kristina Masson. |
Keywords
Acrivon Therapeutics, insider trading, Form 4, stock transaction, beneficial ownership, executive compensation, tax withholding, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.